

hosted by the Missouri Department of Health and Senior Services' Bureau of Immunization Assessment and Assurance www.health.mo.gov/immunizations

webinar series

Rachel C. Orscheln, MD The Importance Of Pediatric Immunizations April 16, 2015

Once upon a time, there was a Magic Kingdom....



Children and families from all over the world visited this magical place.....



Unfortunately, an unwelcome visitor was also circulating...



Measles Virus



Index Case

 11 y.o. unvaccinated child who had visited 2 theme parks in Orange County, CA was hospitalized with measles in December of 2014





Measles

- Measles: RNA virus with 1 serotype
 - Transmission: By direct contact with respiratory droplets
 - Epidemiology: Incidence in the US is low, <120 cases/year, usually imported
 - Illness: Acute illness characterized by:
 - Fever
 - Cough
 - Runny nose
 - Conjunctivitis
 - Erythematous maculopapular rash
 - Koplik spots



- Complications: pneumonia, otitis media, croup, diamiea, encephalitis (1/1000 cases), death (1-3/1000 cases), SSPE (rare degenerative CNS disease)
- Treatment: Vitamin A supplementation is associated with reduced morbidity and mortality



Redbook, 2006

Confirmed Measles Cases by Date of Onset



http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6406a5.htm?s_cid=mm6406a5_w#Fig

Measles Cases by State and Year



Most cases had NO documented measles vaccine

- California cases:
 - 45% were completely unvaccinated
 - 67% intentionally unvaccinated for personal belief
 - 23% were too young to be vaccinated
 - 5% had one dose of measles vaccine
 - 7% had two or more doses of measles vaccine
 - 43% unknown vaccine history
- Twenty percent of patients were hospitalized



2015 Measles Cases in the U.S.

January 1 to April 3, 2015



*Provisional data reported to CDC's National Center for Immunization and Respiratory Diseases



Measles, U.S., 2001-2014* Cumulative Number by Month of Rash Onset



Source: National Notifiable Diseases Surveillance System (NNDSS) and direct report to coc

2014 Outbreak

- 23 Outbreaks of Measles in the US in 2014
- Largest outbreak in Amish community in Ohio affects 383 people
 - Index case is Amish missionary who traveled to the Philippines





Measles in the Philippines



<u>2014</u>

58,010 suspected cases 21,420 confirmed cases 110 deaths

Legend:



No confirmed case With confirmed case No case based data

1 dot = 1 case

Dots are placed at random within the corresponding district, and might not reflect the exact location of the case



The Moral of the Story



"It's a small world after all!"



Objectives

- Review basic vaccinology
- Understand the concept of "herd immunity"
- Review infections prevented by vaccinations and the impact of vaccination programs on these diseases
- Examine controversies related to vaccinations and vaccine refusal



Introduction



- Vaccines are among the most effective preventative health tools
- The success of vaccination programs depends on high rates of uptake
- High immunization coverage results in a decline in vaccine-preventable diseases
- A reduction in these diseases may result in increased complacency about vaccinepreventable diseases



Omer, et al. NEJM. May 7, 2009, Vol. 360:1981-8.

How Vaccines Work

- Weakened or part of a germ is injected
- The immune system recognizes the germ as a "foreign invader" (called antigen) and forms immune proteins (antibodies) to the germ
- If the body faces the real germ in the future, the pre-formed antibodies are prepared to attack and prevent infection







Specific Types of Vaccines

| Type of Vaccine | Description | Example |
|-----------------|--|-------------------------|
| Live-attenuated | Weakened virus which does not cause disease | MMR Varicella Flu |
| Inactivated | Inactivated (killed) virus | Polio |
| Toxoid | Weakened toxin from bacteria | Tetanus |
| Subunit | Contains part of bacteria or virus | Pertussis |
| Conjugate | Target polysaccharide (sugar-like) coating on bacteria by connecting (conjugating) them to antigens the developing immunes system can recognize | Pneumococcal HiB |



If I don't vaccinate my child, won't they be protected by "Herd Immunity"?





Herd Immunity

"The <u>resistance of a group</u> attacked by a disease because of the <u>immunity of a large proportion of</u> <u>the members</u> and consequent lessening of the likelihood of an infected individual coming into contact with a susceptible individual."



Rashid, et al. Curr Opin Infect Dis. 2012, Vol. 25:243-249.

Herd Immunity

- Determinants
 - *R*₀ = The average number of individuals each infected person will infect in susceptible population
 - $1-1/R_0$ = The proportion needed to vaccinate to eliminate infection
 - E = vaccine effectiveness
 - $(1-1/R_0)/E$ = critical vaccine coverage
 - Measles
 - (1-1/12)/0.95=96%

http://practice.sph.umich.edu/micphp/epicentral/basic_reproduc_rate.php



Rashid, et al. Curr Opin Infect Dis. 2012, Vol. 25:243-249.

Herd Immunity



Kim, et al. Scand J Infect Dis. 2011, Vol. 43:683-689.





Recommended Immunization Schedule for Persons Aged 0 to 18 Years

| Vaccine | Birth | 1 mo | 2 mos | 4 mos | 6 mos | 9 mos | 12 mos | 15 mos | 18 mos | 19–23 mos | 2-3 yrs | 4-6 yrs | 7-10 yrs | 11-12 yrs | 13–15 yrs | 16–18 yrs | |
|---|----------------------|--------------------------|---------|----------------------|-------------------------------|---|--|-----------------------------|-----------------|--------------|---------|----------------------------------|----------|--------------------|--------------|--------------|--|
| Hepatitis B ¹ (HepB) | 1 st dose | ≺ 2 nd | dose 🔶 | | | | | | | | | | | | | | |
| Rotavirus ² (RV) RV1 (2-dose series); RV5 (3-dose series) | | | 1ª dose | 2 nd dose | See footnote 2 | | | | | | | | | | | | |
| Diphtheria, tetanus, & acel- Iular pertussis ³ (DTaP: <7 yrs) | | | 1ª dose | 2 nd dose | 3 rd dose | | | <u>←</u> 4 ⁱⁿ | dose — → | | | 5 th dose | | | | | |
| Tetanus, diphtheria, & acel- Iular pertussis ⁴ (Tdap: <u>></u> 7 yrs) | | | | | | | | | | | | | | (Tdap) | | | |
| Haemophilus influenzae type b ^e (Hib) | | | 1ª dose | 2 nd dose | See footnote 5 | | <u>3</u> [™] or 4 See for See for | th dose <u>.</u> | | | | | | | | | |
| Pneumococcal conjugate ⁴ (PCV13) | | | 1ª dose | 2 nd dose | 3 [™] dose | | ← 4° (| dose 🔶 | | | | | | | | | |
| Pneumococcal polysaccha- ride ^d (PPSV23) | | | | | | | | | | | | | | | | | |
| Inactivated poliovirus ⁷ (IPV) (<18 yrs) | | | 1ª dose | 2 rd dose | < | | 3 rd dose | | 4 | | | 4 th dose | | | | | |
| Influenza ^s (IIV; LAIV) 2 doses for some: See footnote 8 | | | | | Annual vaccination (IIV only) | | | | | | | Annual vaccination (IIV or LAIV) | | | | | |
| Measles, mumps, rubella ^o (MMR) | | | | | | | ≺ 1*a | iose 🔶 🔸 | | | | 2 nd dose | | | | | |
| Varicella ¹⁰ (VAR) | | | | | | | ≺ 1*c | iose> | | | | 2 rd dose | | | | | |
| Hepatitis A ¹¹ (HepA) | | | | | | | <mark>∢</mark> -2 | dose series, S | See footnote | 11—→ | | 1 | 1 | | | | |
| Human papillomavirus ¹² (HPV2: females only; HPV4: males and females) | | | | | | | | | | | | | | (3-dose series) | | | |
| Meningococcal ¹³ (Hib-Men- CY \geq 6 weeks; MenACWY-D \geq 9 mos; MenACWY-CRM \geq 2 mos) | | | | | See footnote 13 | | | | | | | | | 1ª dose | | Booster | |
| Range of recommended ages for ages for catch-up ages for certain high-risk groups | | | | | | Range o during v encoura high-risk | e of recommended ages Not routinely ig which catch-up is recommended uraged and for certain risk groups | | | | | | | | | | |



http://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-schedule.pdf

Hepatitis B Virus



- Transmission: Contact with blood or body fluids
- Disease state:
 - Acute: Liver dysfunction with fever, jaundice, malaise, nausea, vomiting, and abdominal pain
 - Chronic: Duration of infection dependent on age at acquisition (90% of infants vs. 5% of adults)
 - Outcome:
 - Cirrhosis or liver cancer occurs in 25% of chronic childhood infections and 15% of chronic adult infections





http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm#overview

Hepatitis B Virus



 Vaccine: 3 doses (birth, 1 month, and 6 months)



- Vaccine efficacy:
 - Infants: 95% develop protective immunity
 - Adults < 40 years: 90%
 develop protective
 immunity

http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm#overview Redbook, 2006. http://www.dpd.cdc.gov/vaccines/pubs/pinkbook/hepb.html#rea ctions





Rotavirus



- Transmission: Fecal-oral
- Disease: Fever, vomiting, watery diarrhea (3-8 days), abdominal pain
- Epidemiology:
 - Most common cause of severe diarrhea among children



- Vaccine: Live, oral, 2 or 3 doses
- Efficacy: 85-98% effective against severe disease



http://www.cdc.gov/rotavirus/

Diphtheria



- **Diphtheria:** Caused by toxigenic strains of *Corynebacteria diphtheriae*
 - Transmission: Respiratory droplet or contact with skin lesions
 - Illness:
 - Membranous nasopharyngitis or obstructive laryngotracheitis
 - Absorbed toxin affects heart and brain
 - Treatment: Anti-toxin, erythromycin or penicillin
 - Outcome:
 - Death in 1 in 10





http://www.vaccineinformation.org/photos/diphiac001.jpg



Diphtheria Epidemiology



Diphtheria Hotspots 1997 - present; cases reported to the WHO

- Over 100 reported cases
- Between 50 and 100 reported cases
- Betweem 1 and 49 reported cases
- No cases reported



http://en.wikipedia.org/wiki/File:Diphterie.png

Tetanus

- Tetanus: Caused by bacterium *Clostridium tetani*
 - Transmission: Contamination of wounds
 - Illness:
 - Generalized tetanus (Lockjaw): Neurologic disease with severe muscle spasms
 - Localized tetanus: Localized muscle spasms
 - Treatment:
 - Wound and supportive care
 - Tetanus immune globulin
 - Antibiotics
 - Outcome:
 - Death in 1 in 5





Pertussis

- Pertussis: Caused by Bordetella pertussis
 - Transmission: Respiratory droplets
 - Illness: Respiratory tract illness in phases:
 - Catarrhal: cold symptoms
 - Paroxysmal: paroxysms of cough followed by inspiratory whoop and vomiting
 - Convalescent: symptoms wane over weeks to months
 - Apnea and sudden death in infants without many other symptoms
 - Treatment:
 - Supportive care
 - Antibiotics: Macrolide antibiotics
 - Outcome:
 - Pneumonia in 1 in 4
 - Encephalopathy in 1 in 300
 - Death in 1-2 in 100

Redbook, 2006



http://www.co.dakota.mn.us/Departments/PublicHealth/News/Nov08.htm



Pertussis Epidemiology



Pertussis and Vaccine Refusal **PEDIATRICS** OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Nonmedical Vaccine Exemptions and Pertussis in California, 2010 Jessica E. Atwell, Josh Van Otterloo, Jennifer Zipprich, Kathleen Winter, Kathleen Harriman, Daniel A. Salmon, Neal A. Halsey and Saad B. Omer *Pediatrics* 2013;132;624; originally published online September 30, 2013; DOI: 10.1542/peds.2013-0878

- Evaluated the relationship between Nonmedical exemptions (NME) and pertussis outbreaks
 - Geocoded NME for vaccination for schools during the 2005-6 through 2009-10 school years
 - Geocoded confirmed, probable, and suspected cases of pertussis in 2010



PEDIATRICS[®]

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Nonmedical Vaccine Exemptions and Pertussis in California, 2010 Jessica E. Atwell, Josh Van Otterloo, Jennifer Zipprich, Kathleen Winter, Kathleen Harriman, Daniel A. Salmon, Neal A. Halsey and Saad B. Omer *Pediatrics* 2013;132;624; originally published online September 30, 2013; DOI: 10.1542/peds.2013-0878

- From 2000 to 2010 NME rates tripled
- NME as high as 84% in some schools
- >95% vaccine coverage rate is necessary for prevention of outbreaks
- Clusters of pertussis outbreaks overlapped significantly with areas with high rates of NME



Diphtheria, Tetanus, Pertussis

- Vaccine recommendations: 5 doses (2, 4, 6, 15-18 mos, and 4-6 years)
 - Tdap booster at 11 years
 - Tdap with pregnancy
- Efficacy:
 - Tetanus 100%
 - Diphtheria 95%
 - Pertussis 80-85%





Haemophilus influenzae type B

- Transmission: Respiratory droplet or direct contact with respiratory secretions
- Disease states:
 - Pneumonia
 - Sepsis
 - Meningitis (8-10K cases/year)
 - Epiglottitis
 - Bone and joint infections
 - Cellulitis
 - Otitis media
- Treatment: Antibiotics
- Outcome:
 - Death in 3-6%
 - Permanent disability in 30% of meningitis
- Vaccine: 3 or 4 doses
- Efficacy: 95-100%



immunizations/
Streptococcus pneumoniae

- Transmission: Respiratory droplet
- Disease states:
 - Otitis media (most common)
 - Sinusitis
 - Pneumonia
 - Meningitis
 - Skin and eye infections
 - Bone and joint infections
- Treatment: Antibiotics
- Vaccine: 4 dose series
- Efficacy: > 90% against invasive disease





Poliovirus

- Viruses: Enteroviruses of 3 serotypes, 1, 2, and 3
- Transmission: Fecal-oral and respiratory
- Disease states:
 - 95% of infections are asymptomatic
 - 4-8% non-specific illness with fever and pharyngitis
 - 1-5% aseptic meningitis
 - 0.1-2% assymmetric acute flaccid paralysis with areflexia of the affected limb (2/3 will have residual paralytic polio)



- Vaccine: 4 dose series
- Efficacy: 99-100%









Poliovirus 2008

Poliovirus 1988





Influenza



- Viruses:
 - Influenza A: Subtyped based on 2 surface proteins •
 - Hemaglutinin (16 subtypes)
 - Neuraminidase (9 subtypes)
 - Influenza B
- Transmission: Respiratory droplets
- Illness: "The Flu"
 - Fever -Headache -Fatigue
 - Myalgias -Cough -Sore throat
 - Congestion -Gastrointestinal complaints

- Treatment: Antivirals
- Complications on Influenza:
 - Bacterial pneumonia
 - Ear and sinus infections
 - Asthma exacerbation
- Yearly influenza mortality:
 - 3,000-49,000 deaths per year in the US
 - Up to 350 pediatric deaths each year



Influenza



- Vaccines:
 - Inactivated influenza vaccine (IIV), trivalent and quadrivalent
 - Live-attenuated influenza vaccine (LAIV4), quadrivalent
 - Recommendations: Yearly vaccine (2 doses for first year if < 9 years)
- Vaccine efficacy depends on:
 - Host status
 - Match of vaccine to strains
 - Type of vaccine given:
 - LAIV> IIV
 - 50-90% when strains wellmatched





Mumps

- Mumps: RNA virus
 - Transmission: Respiratory secretions
 - Epidemiology: <300 cases/year
 - Illness:
 - Swelling of the glands
 - Meningitis
 - Orchitis
 - Treatment: Supportive care
 - Outcome:
 - Death is rare
 - Deafness in 1 in 20,000
 - Sterility in post-pubertal males (rare)



Mumps: Note the bilateral parotid and submandibular gland enlargement.



Rubella

- Rubella: RNA virus
 - Transmission:
 - Respiratory droplet
 - Congenital infection
 - Epidemiology:
 - Before vaccine: epidemic disease
 - Post-vaccine: <25 cases/year (99% reduction in incidence)
 - Illness (aka German measles or 3-day measles)
 - Fever
 - Rash
 - Arthritis
 - Lymphadenopathy
 - Rarely: Encephalitis or low platelet cou
 - Congenital rubella syndrome







MMR

- Vaccine: MMR is a live, attenuated, 3 component vaccine
- Vaccine recommendations: 2 doses (12-15 mos and 4-6 years)
- Efficacy: 99% for Measles and 95% for Mumps and Rubella





Varicella



- Virus: Varicella-zoster virus of the herpesvirus family
- Transmission: Airborne spread or by direct contact
- Illness:
 - Chicken pox
 - Shingles
- Epidemiology: Pre-vaccine era, most infections occurred in cmiaren <10 years
 - 1/500 children hospitalized
 - 1/50 adults hospitalized
 - 1/100,000 children died
 - Pneumonia
 - Bacterial superinfection
 - Hepatitis
 - Encephalitis
- Treatment: supportive and antivirals for certain patients





Varicella



- Vaccine: Varicella vaccine is a live-attenuated virus vaccine
- Vaccine recommendations: 2 doses (12-15 mos and 4-6 years)
- Efficacy:
 - Prevents chicken pox in 70-90%
 - Prevents severe varicella in 95%



Varicella Reported by year for 4 States



Hepatitis A Virus



http://commons.wikimedia.org/wiki/File:Hepatitis_A_virus_01.jpg

- Transmission: Person-to-person by fecal-oral route
- Epidemiology: Prior to vaccination, approximately 20 K cases/year in the US with 100 deaths
- Disease:
 - Asymptomatic in young children
 - Acute hepatitis with fever, malaise, jaundice, anorexia, and nausea
 - Fulminant hepatitis may occur but is rare
- Treatment: supportive care
- Vaccine: 2 doses
- Efficacy: 94-100%



Redbook, 2006

http://www.cdc.gov/vaccines/vpd-vac/hepa/downloads

Meningococcus



http://www.nature.com/na ture/journal/v404/n6777/fi g_tab/404451a0_F1.html

- *Neisseria meningiditis:* Gram-negative bacterial infection with at least 13 serogroups
- Transmission: Person-to-person through respiratory droplets.
- Epidemiology:
 - Peak occurrences:
 - < 5 years of age (peak attack rate age < 1 year)
 - Adolescents 15-18
 - Freshman college students in dorms have higher rates than non-college students





Meningococcus



- Disease states:
 - Asymptomatic colonization is common
 - Invasive infections:
 - Meningococcemia: Abrupt onset of fever, chills, malaise, prostration, and rash
 - Meningococcal meningitis
- Treatment: Antibiotics and supportive care
- Vaccines: 2 dose series for routine vaccination at age 11 and 16 years



Human Papillomaviruses



- Epidemiology:
 - Anogenital HPV is most common STD (occurring in >40% of sexually active females)
- Disease states:
 - Clinically unapparent infection \rightarrow Cervical dysplasia
 - Cervical cancer (12,000 cases/year with 4000 deaths)
 - Penile cancer
 - Head and neck cancer
 - Anogenital warts
 - Respiratory tract papillomatosis
- Vaccines: Inactivated subunit
 - Bivalent- HPV 16 and 18
 - Quadrivalent- HPV 6, 11, 16, 18



Summary- Part 1

- Diseases prevented by vaccination are serious
- Most of these infections continue to be in transmission in the US
- Vaccinations are an effective strategy to prevent these diseases
- Herd immunity provides an additional layer of protection, especially for the most vulnerable







Are vaccines safe?

- Minor side effects are possible for all vaccines: pain, redness, tenderness at the site of injection
- Serious side effects are uncommon and unlikely to be permanent
 - Pertussis vaccine: crying, high fever, febrile seizure
 - Hepatitis B vaccine: anaphylaxis in 1 in 600,000



Are vaccines safe?

| Comparison | Adverse Event | Odds | | | | |
|------------------|--|----------------|--|--|--|--|
| Measles | Pneumonia | 6 in 100 | | | | |
| | Encephalitis | 1 in 1,000 | | | | |
| | Death | 2 in 1,000 | | | | |
| MMR | Encephalitis or severe allergic reaction | 1 in 1,000,000 | | | | |
| Living in the US | Lightning strike | 1 in 960,000 | | | | |
| Walking | Dying | 1 in 54,538 | | | | |
| | http://wallpapersinhq.com/40923-lightning_stri | | | | | |



http://www.cdc.gov/vaccines http://www.lightningsafety.noaa.gov/odds.htm http://www.economist.com/blogs/graphicdetail/2013/02/daily-chart-7

Recommended Immunization Schedule for Persons Aged 0 to 18 Years

| Vaccine | Birth | 1 mo | 2 mos | 4 mos | 6 mos | 9 mos | 12 mos | 15 mos | 18 mos | 19–23 mos | 2-3 yrs | 4-6 yrs | 7-10 yrs | 11-12 yrs | 13–15 yrs | 16–18 yrs | |
|---|----------------------|--------------------------|---------|----------------------|----------------------|-------|-------------------------------------|-----------------------------|-----------------|--------------|----------------------|----------------------------------|----------|--------------------|--------------|--------------|--|
| Hepatitis B ¹ (HepB) | 1 st dose | ≺ 2 nd | dose 🔶 | | | | | | | | | | | | | | |
| Rotavirus ² (RV) RV1 (2-dose series); RV5 (3-dose series) | | | 1ª dose | 2 nd dose | See footnote 2 | | | | | | | | | | | | |
| Diphtheria, tetanus, & acel- Iular pertussis ³ (DTaP: <7 yrs) | | | 1ª dose | 2 nd dose | 3 rd dose | | | <u>←</u> 4 ⁱⁿ | dose — → | | | 5 th dose | | | | | |
| Tetanus, diphtheria, & acel- Iular pertussis ⁴ (Tdap: <u>></u> 7 yrs) | | | | | | | | | | | | | | (Tdap) | | | |
| Haemophilus influenzae type b ^e (Hib) | | | 1ª dose | 2 nd dose | See footnote 5 | | <u>3</u> [™] or 4 See for | th dose <u>.</u> | | | | | | | | | |
| Pneumococcal conjugate ⁴ (PCV13) | | | 1ª dose | 2 nd dose | 3 [™] dose | | ← 4° (| dose 🔶 | | | | | | | | | |
| Pneumococcal polysaccha- ride ^d (PPSV23) | | | | | | | | | | | | | | | | | |
| Inactivated poliovirus ⁷ (IPV) (<18 yrs) | | | 1ª dose | 2 rd dose | < | | 3 rd dose | | 4 | | | 4 th dose | | | | | |
| Influenza ^s (IIV; LAIV) 2 doses for some: See footnote 8 | | | | | | А | nnual vaccin | ation (IIV only | n | | | Annual vaccination (IIV or LAIV) | | | | | |
| Measles, mumps, rubella ^o (MMR) | | | | | <1≝dose> | | | | | | | 2 nd dose | | | | | |
| Varicella ¹⁰ (VAR) | | | | | <1≭dose> | | | | | | 2 rd dose | | | | | | |
| Hepatitis A ¹¹ (HepA) | | | | | < | | | | | | | 1 | 1 | | | | |
| Human papillomavirus ¹² (HPV2: females only; HPV4: males and females) | | | | | | | | | | | | | | (3-dose series) | | | |
| Meningococcal ¹³ (Hib-Men- CY \geq 6 weeks; MenACWY-D \geq 9 mos; MenACWY-CRM \geq 2 mos) | | | | | See footnote 13 | | | | | | | | | 1ª dose | | Booster | |
| Range of recommended ages for ages for catch-up ages for catch-up is recommended ages for catch-up is recommended ages for catch-up is recommended ages for certain high-risk ages for | | | | | | | | t routinely ommende | d | | | | | | | | |



http://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-schedule.pdf

1970 Recommended US Childhood Immunization Schedule

Range o frecommended age c

Preadole coen ta cœ comen t

| Vaccine | Birth | 1 mo | 2 mos | 4 mos | 6 mos | 12 mos | 15 mos | 18 mos | 24 mos | 4-6 угз | 11- 12 yrs | 13- 18 yıs |
|-------------------------|-------|---------|----------|----------|----------|-----------|-----------|-----------|-----------|------------|------------------|------------------|
| Diphtheria, tetanus, | | | | | | | | | | | | |
| pertussis | | | DTP | DTP | DTP | | רס | rp | | DTP | Td | |
| Oral polio | | | OPV | OPV | OPV | | | OPV | | OPV | | |
| Measles | | | | | | Mea | sles | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | imn | nunizati | ions//// |

Adapted from Centers for Disease Control and Prevention (CDC).

Do vaccines overwhelm the immune system?

- The immune system is primed *in utero* to respond to antigens
- The neonate in challenged with multiple antigens from the moment of birth



https://adelaidebirth.wordpress.com/2013/07/20/the-child-birth-photograph-victoria-berekmeri-adelaide-birth-photographer/



Chatterjee and O'Keefe, *Expert Rev Vaccines*. 2010, Vol 9 (5):497-502.

Do vaccines overwhelm the immune system?



- The immune system can respond to billions of antigens
 - 10,000,000 B-cells are present in every mL of blood
 - Each B-cell can produce enough new B-cells to make an effective vaccine response (10 ng/mL of antibody) in one week
 - Vaccines in use today contain between 1 and 70 antigens per vaccine
- If 11 vaccines were given all at once, this would temporarily use only 0.1% of this arm of the immune system

Do vaccines overwhelm the immune system?

Current vaccines have fewer antigens than older vaccines

| 1900 | | 1960 | | 1980 | | 2000 | | | |
|----------|----------|----------|----------|----------|----------|----------|-----------------------------------|--|--|
| Vaccines | Proteins | Vaccines | Proteins | Vaccines | Proteins | Vaccines | Proteins/ p olysaccharides | | |
| 1 | 200 | 5 | 3217 | 7 | 3041 | 11 | 126 | | |

Vaccines contain far less antigens than any natural infection







What is Autism?

- Developmental disorder with the following characteristics:
 - Social impairments
 - Communication difficulties
 - Restricted, repetitive, and stereotyped patterns of behavior
 - Most often identified in toddlers from 18 to 30 months of age



What is the cause of Autism?

- ?????
 - Genetics
 - Twin studies show increased concordance with identical twins
 - Increased risk if sibling is affected
 - Parents and siblings of autistic children often exhibit mild traits on sensitive testing
 - Males affected at a rate of 4:1 compared to females





Do vaccines cause Autism?

- The Wakefield Study:
 - 1998- Dr. Andrew Wakefield published paper describing 12 children with bowel symptoms and developmental disorders that he linked to the MMR vaccine





The Wakefield Study

- Wakefield was paid by lawyer seeking to sue vaccine manufacturers for 2 years prior to study (total sum paid \$750,000)
- Most patients in the study were contacts of lawyer (not sequentially presenting patients as presented)
- Wakefield was seeking patent on mono-valent measles vaccines at the same time



The Wakefield Study

- Data was fabricated when compared to actual patient medical records
 - Onset of developmental concerns was altered to fit timing after MMR
 - 5/12 had pre-existing developmental concerns
 - Developmental symptoms were reported to have occurred within days of MMR, but records showed concerns months later
 - GI symptoms developed after diagnosis of autism in 4/12 patients
 - Abnormal pathological findings reported by Wakefield were actually normal
- Paper was retracted and Wakefield lost his license to practice medicine



Vaccines are not the cause of Autism!

 Developmental disorders are diagnosed in childhood and vaccines are given during childhood







 Multiple studies in the US and Europe have found no association between the MMR and autism



Vaccines are not the cause of Autism!

- Multiple studies demonstrate NO LINK between MMR and autism:
 - 59 studies between 2004-2011
 - 14,700,000 children
 - Multiple countries



Vaccines are not the cause of Autism!

- Home movie studies:
 - Review of home videos of 1st
 B-day
 - Blinded comparison of children with autism to typically developing children
 - Investigators can identify autistic children (prediagnosis)
 - MMR is typically given AFTER
 1st birthday



immunizations/

Vaccines are not the cause of Autism?

- Reported rates of autism may have increased
 - Change in diagnostic criteria
 - Increased awareness
 - Increased availability of services
- Rates of vaccination have been stable



Do vaccines contain unnecessary additives?

- Vaccines contain preservatives and additives to keep the product sterile and increase efficacy
- The amount of chemical additives is small
 - Aluminum salts:
 - Increase vaccine efficacy
 - Amount in vaccine = amount in 32 oz of infant formula
 - Formaldehyde:
 - Inactivates viruses and detoxifies bacteria
 - Amount in vaccine similar to what is naturally in the human blood stream



Do vaccines contain unnecessary additives?

- Polyethelene glycol:
 - Viral inactivator and vaccine purifier
 - Found in many household products like toothpaste
- Thimerosol
 - Mercury containing preservative
 - Metabolizes to ethylmercury (different from environmental neurotoxin methylmercury)
 - Numerous studies demonstrate NO LINK to developmental disorders
 - Thimerosol has been removed from pediatric vaccines



Does my child need vaccines if I breastfeed?

- Breastfeeding provides numerous benefits to health including reducing risk of disease:
 - Bacteremia
 - Diarrhea
 - Respiratory tract infection
 - Otitis media
 - Urinary tract infection
 - Late-onset sepsis in preterm infants
 - Necrotizing enterocolitis
 - Type 1 and type 2 diabetes
 - Lymphoma, leukemia, and Hodgkins disease
 - Childhood overweight and obesity



Breastfeeding Report Card United States/2013

immunizations/

Does my child need vaccines if I breastfeed?

- Breastfeeding is insufficient protection against vaccine preventable diseases
- Breastfeeding and vaccinations work synergistically
 - Breastfeeding boosts immune responses to some vaccines
 - Breastfeeding is associated with a decreased pain response in infants


What About Delaying Vaccines?

- There is no benefit to delaying vaccines
- Delaying vaccines results in:
 - Increased window of vulnerability for the most vulnerable
 - Increased exposure to infectious diseases through increased number of office visits
 - Increased painful encounters



Summary

- Vaccines are among the most effective preventative health tools
- High rates of vaccination within a community result in protection for those who cannot be vaccinated
- When rates of vaccination fall, diseases reemerge
- Refusal of vaccination often results from misunderstanding regarding the benefits of vaccination

